Abediterol (INN) is an experimental drug candidate for the treatment of asthma and chronic obstructive pulmonary disease. It is currently under development by the Spanish pharmaceutical company Almirall and is in Phase II clinical trials. It acts as a β2-adrenergic agonist.
This page contains content from the copyrighted Wikipedia article "Abediterol"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
